Kisqali offers survival benefit for breast cancer patients, finds study
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus…
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months over fulvestrant alone.